Open AccessPB1878: CROSS‐TRIAL ANALYSIS OF FIXED‐DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Author(s) -
Barrientos J. C.,
Barr P. M.,
Mato A. R.,
Tam C. S.,
Ghia P.,
Moreno C.,
Kay N. E.,
Siddiqi T.,
SzaferGlusman E.,
Zhou C.,
Neumayr L.,
Krigsfeld G.,
Wierda W. G.,
Shanafelt T.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850364.78915.d9
Subject(s) - medicine , fludarabine , regimen , gastroenterology , cyclophosphamide , cohort , rituximab , venetoclax , chronic lymphocytic leukemia , chemotherapy , leukemia , lymphoma